Literature DB >> 21904785

Diffuse alveolar damage in patients with dermatomyositis: a six-case series.

Yuko Matsuki1, Hiroyuki Yamashita, Yuko Takahashi, Toshikazu Kano, Arisa Shimizu, Kenji Itoh, Hiroshi Kaneko, Akio Mimori.   

Abstract

The clinical course of diffuse alveolar damage (DAD) was studied in six consecutive cases of dermatomyositis (DM) based on our hospital records over 8 years. Three patients had severe myopathy at presentation, and the other three patients showed clinically amyopathic DM (CADM). Interstitial pneumonia in all patients developed shortly after they manifested DM. DAD in five deceased patients, which was proven pathologically, did not respond to steroid therapy combined with cyclosporine or tacrolimus. Of these, two patients began receiving combination therapy before suffering respiratory symptoms, and one of them had elevated serum Krebs von der Lungen-6 (KL-6) levels before visible abnormalities appeared on a plain chest X-ray. Only one patient with CADM survived; this patient received intravenously administered pulse cyclophosphamide (IVCY) therapy intravenously for DAD from the early stage. Delayed adjunctive IVCY was ineffective for progressed DAD in the remaining five patients. Elevated serum ferritin levels were observed in all four patients examined and might have predicted the lethal DAD, as in a previous report. In conclusion, promptly beginning IVCY therapy may be beneficial for patients with DM and interstitial pneumonia who show elevated serum levels of ferritin or KL-6 with minimal pulmonary abnormalities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904785     DOI: 10.1007/s10165-011-0502-z

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  7 in total

Review 1.  Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach.

Authors:  Biplab K Saha; Woon H Chong; Nils T Milman
Journal:  Clin Rheumatol       Date:  2021-09-07       Impact factor: 3.650

Review 2.  [Interstitial lung disease in polymyositis/dermatomyositis].

Authors:  A Schnabel
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

Review 3.  Anti-MDA5 Antibody Spectrum in Western World.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Curr Rheumatol Rep       Date:  2018-10-31       Impact factor: 4.592

4.  Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.

Authors:  Yuka Ogawa; Dai Kishida; Yasuhiro Shimojima; Koichi Hayashi; Yoshiki Sekijima
Journal:  Case Rep Rheumatol       Date:  2017-10-31

5.  Polymyositis Presenting as Rhabdomyolysis After the Initiation of Omeprazole.

Authors:  Jonathan K Jakubowski; Rosemina Patel; Venkata Buddharaju
Journal:  Cureus       Date:  2020-05-14

6.  Acute respiratory distress syndrome relapsing in 10 months with an initial manifestation of polymyositis.

Authors:  Yukihisa Takeda; Mariko Ono; Hayato Kinoshita; Yoko Nagatomo; Hiroki Miyauchi; Hiroshi Tsukamoto; Hiroyuki Nakamura; Kazutetsu Aoshiba
Journal:  Clin Case Rep       Date:  2021-12-06

Review 7.  Pathological interpretation of connective tissue disease-associated lung diseases.

Authors:  Kun Young Kwon
Journal:  Yeungnam Univ J Med       Date:  2019-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.